Together, these findings establish piR-hsa-8393202 and piR-hsa-8429916 as stable, tumor-derived circulating piRNAs that exert pro-oncogenic effects in LUAD, promoting tumor cell proliferation and survival while maintaining excellent molecular stability suitable for clinical biomarker application. Here, PIR is linked to neoplasm.